

Annex C: NME Oncology drugs approved by USFDA from Jan 2011 to Dec 2013: prices, country or manufacturer, and other meta data

Brand Name	Active ingredient	NDA / BLA	FDA No.	Date of Registration	Cost per Course (or 1 year)	Review Class	Company	Parent company country	Orphan Drug Exclusivity	FDA PR, trials, efficacy	FDA PR, trials, safety
Yervoy	ipilimumab	BLA	125377	2011-03-25	\$123,625	P	BRISTOL MYERS SQUIBB	USA	Yes	676	676
Caprelsa	vandetanib	NDA	22405	2011-04-06	\$124,064	P	IPR PHARMS INC (AstraZeneca PLC)	UK	Yes	331	331
Zytiga	abiraterone acetate	NDA	202379	2011-04-28	\$77,810	P	JANSSEN BIOTECH (J&J)	USA		1088	1088
Adcetris	brentuximab vedotin	BLA	125399	2011-08-19	\$108,900	P	SEATTLE GENETICS	USA	Yes	160	160
Xalkori	crizotinib	NDA	202570	2011-08-26	\$125,967	P	PFIZER	USA	Yes	255	255
Ferriprox	deferiprone	NDA	21825	2011-10-14	\$168,274	S	APOPHARMA INC (Apotex)	Canada	Yes	236	236
Jakafi	ruxolitinib	NDA	202192	2011-11-16	\$92,832	P	INCYTE CORP	USA	Yes	528	528
Erwinaze	asparaginase Erwinia chrysanthemi	BLA	125359	2011-11-18	\$393,295	P	EUSA PHARMA USA (Jazz)	Ireland	Yes	58	58
Voraxaze	glucarpidase	BLA	125327	2012-01-17	\$94,500	P	BTG INTERNATIONAL INC (B2Gold)	UK	Yes	22	290
Inlyta	axitinib	NDA	202324	2012-01-27	\$223,205	S	PFIZER	USA		723	723
Erivedge	vismodegib	NDA	203388	2012-01-30	\$19,163	P	GENENTECH (Roche)	Switzerlan		96	96
Perjeta	pertuzumab	BLA	125409	2012-06-08	\$81,513	P	GENENTECH (Roche)	Switzerlan		808	808
Kyrpolis	carfilzomib	NDA	202714	2012-07-20	\$66,320	S	ONYX PHARMS (Amgen)	USA	Yes	266	266
Zaltrap	ziv-aflibercept	BLA	125418	2012-08-03	\$33,600	P	SANOFI AVENTIS US	France		1226	1226
Neuroval	tbo-filgrastim	BLA	125294	2012-08-29		S	SICOR BIOTECH (Teva)	Israel		348	680
Xtandi	enzalutamide	NDA	203415	2012-08-31	\$15,645	P	ASTELLAS	Japan		1199	1199
Bosulif	bosutinib	NDA	203341	2012-09-04	\$99,539	S	WYETH PHARMS INC (Pfizer)	USA	Yes	546	546
Stivarga	regorafenib	NDA	203085	2012-09-27	\$28,050	P	BAYER HLTHCARE	Germany	Yes	199	199
Synribo	omacetaxine mepesuccinate	NDA	203585	2012-10-26	\$23,380	S	IVAX INTL (TEVA)	Israel	Yes	76	76
Cometriq	cabozantinib	NDA	203756	2012-11-29	\$32,263	P	EXELIXIS	USA	Yes	330	330
Icusig	ponatinib	NDA	203469	2012-12-14	\$116,557	P	ARIAD	USA	Yes	449	449
Pomalyst	pomalidomide	NDA	204026	2013-02-08	\$62,332	S	CELGENE	USA	Yes	221	221
Kadcyla	ado-trastuzumab emtansine	BLA	125427	2013-02-22	\$150,882	P	GENENTECH (Roche)	Switzerlan		991	991
Lymphoseek	technetium Tc Radium Ra 223 dichloride	NDA	202207	2013-05-13		S	NAVIDEA BIOPHARMS	USA	Yes	332	332
Xofigo	Radium Ra 223 dichloride	NDA	203971	2013-05-15	\$69,000	P	BAYER HLTHCARE	Germany		809	809
Mekinist	Trametinib	NDA	204114	2013-05-29	\$105,850	S	GLAXOSMITHKLINE LLC	UK	Yes	322	322
Tafinlar	dabrafenitb	NDA	202806	2013-05-29	\$92,467	S	GLAXOSMITHKLINE LLC	UK	Yes	250	250
Gazyva	obinutuzumab	BLA	125486	2013-11-01	\$41,300	P	GENENTECH (Roche)	Switzerlan	Yes	351	
Imbruvica	ibrutinib	NDA	205552	2013-11-13	\$130,000	P	Johnson & Johnson, Pharmacyclics	USA	Yes	48	
	NDA: 20			Average price, all drugs:	\$100,012				Average:	446	
	BLA: 9			Median price, all drugs:	\$92,832				Median:	331	
	Priority: 19			Orphan: 20				USA: 13			
	Standard: 10			Not Orphan: 9				Not USA: 16			